Compare NKLR & TOI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NKLR | TOI |
|---|---|---|
| Founded | 2018 | 2007 |
| Country | Italy | United States |
| Employees | N/A | 641 |
| Industry | Metal Fabrications | Medical/Nursing Services |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 500.6M | 579.9M |
| IPO Year | N/A | N/A |
| Metric | NKLR | TOI |
|---|---|---|
| Price | $4.77 | $5.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $15.00 | $6.67 |
| AVG Volume (30 Days) | 259.4K | ★ 2.1M |
| Earning Date | 04-01-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $30.15 |
| Revenue Next Year | N/A | $25.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.73 | $2.32 |
| 52 Week High | $12.43 | $6.67 |
| Indicator | NKLR | TOI |
|---|---|---|
| Relative Strength Index (RSI) | 45.12 | 55.18 |
| Support Level | $3.94 | $2.90 |
| Resistance Level | $5.20 | N/A |
| Average True Range (ATR) | 0.36 | 0.43 |
| MACD | 0.05 | 0.02 |
| Stochastic Oscillator | 55.84 | 38.34 |
Terra Innovatum Global NV is a micro modular nuclear solutions company that aims to deliver reliable, low-cost and zero-carbon power wherever energy demand is present through its first-of-a-kind reactor SOLO. SOLO is compact yet extremely powerful with one unit generating 1MWe of power, while designed with the strictest safety characteristics and the ability to run 24/7 without the need to refuel for 15 years. Its modular design aims to achieve maximum energy efficiency while significantly reducing the levelized cost of energy (LCOE). SOLO is built using off-the-shelf components and widely available fuel, low-enriched uranium (LEU), which de-risks its regulatory and commercial pathway.
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.